Citigroup Inc. Reiterates Buy Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by stock analysts at Citigroup Inc. in a report issued on Friday. They currently have a GBX 4,900 ($83.46) target price on the stock. Citigroup Inc.’s price objective would indicate a potential upside of 10.78% from the company’s current price.
AstraZeneca plc (LON:AZN) opened at 4407.2881 on Friday. AstraZeneca plc has a 52-week low of GBX 3086.50 and a 52-week high of GBX 5750.00. The stock has a 50-day moving average of GBX 4383.58 and a 200-day moving average of GBX 4061.62. The company’s market cap is £55.576 billion.
AZN has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “underweight” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 3,700 ($63.02) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 3,950 ($67.28) price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Thursday, June 26th. They now have a GBX 4,400 ($74.94) price target on the stock. Seven research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of GBX 3,990.48 ($67.97).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.